NEW YORK (GenomeWeb News) - Elan Pharmaceuticals has joined the MetaTox Consortium, a group spearheaded by informatics firm GeneGo that aims to address the reasons behind the failure of investigational drugs in clinical trials.
 
GeneGo said the consortium includes members from industry and the US Food and Drug Administration and will focus on using systems biology tools and informatics to assess the safety of small molecule compounds and therapeutics.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.